Volume 8, Issue 6

Newer NNRTI Agents in Clinical Practice

In this issue:

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?

Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.

Learning objectives:

  • Discuss the risk factors associated with virologic failure with long-acting injectable cabotegravir and rilpivirine.
  • Describe the weight and metabolic effects of doravirine compared to other ARVs.

Author:

Darcy Wooten, MD
Darcy Wooten, MD

Associate Professor of Medicine
University of California, San Diego
La Jolla, CA

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Launch date: May 31, 2023
Expiration date: May 30, 2025